$EKSO
EKSO BIONICS HOLDINGS, INC. Stock $ekso

$ekso Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-K Financial Statement

#000114420418014386 Filed on March 13, 2018

Income Statement

Concept	2017 Q4	2017 Q3	2017 Q1
Revenue	$2.453M	$1.597M	$1.436M
YoY Change	-5.18%	0.06%	-83.08%
Cost Of Revenue	$1.680M	$1.053M	$1.077M
YoY Change	-3.45%	-11.74%	237.62%
Gross Profit	$777.0K	$544.0K	$352.0K
YoY Change	-7.83%	34.99%	-76.5%
Gross Profit Margin	31.68%	34.06%	24.51%
Selling, General & Admin	$6.880M	$5.640M	$5.620M
YoY Change	26.7%	11.62%	-6.18%
% of Gross Profit	885.46%	1036.76%	1596.59%
Research & Development	$1.990M	$1.986M	$2.870M
YoY Change	-13.1%	-10.38%	33.55%
% of Gross Profit	256.11%	365.07%	815.34%
Depreciation & Amortization	$430.0K	$420.0K	$475.0K
YoY Change	-10.42%	-10.64%	7.95%
% of Gross Profit	55.34%	77.21%	134.94%
Operating Expenses	$8.730M	$7.610M	$8.500M
YoY Change	15.94%	4.69%	4.42%
Operating Profit	-$7.953M	-$7.066M	-$8.148M
YoY Change	18.93%	2.91%	22.67%
Interest Expense	-$390.0K	$165.0K	$119.0K
YoY Change	-2050.0%	1962.5%	1883.33%
% of Operating Profit
Other Income/Expense, Net	-$650.0K	$731.0K	-$70.00K
YoY Change	-159.63%	-145.35%	-102.34%
Pretax Income	-$8.980M	-$6.340M	-$8.300M
YoY Change	60.93%	-25.24%	127.4%
Income Tax
% Of Pretax Income
Net Earnings	-$8.978M	-$6.335M	-$8.302M
YoY Change	61.01%	-25.28%	127.39%
Net Earnings / Revenue	-366.0%	-396.68%	-578.13%
Basic Earnings Per Share		-$0.18
Diluted Earnings Per Share	-$2.239M	-$0.18	-$0.38
COMMON SHARES
Basic Shares Outstanding		34.72M shares	21.90M shares
Diluted Shares Outstanding		34.72M shares	21.90M shares

Balance Sheet

Concept	2017 Q4	2017 Q3	2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$27.81M	$33.44M	$9.430M
YoY Change	65.04%	161.25%	-23.4%
Cash & Equivalents	$27.81M	$33.44M	$9.426M
Short-Term Investments
Other Short-Term Assets	$1.340M	$2.190M	$740.0K
YoY Change	168.0%	253.23%	-26.0%
Inventory	$3.025M	$2.380M	$1.819M
Prepaid Expenses
Receivables	$2.760M	$2.170M	$1.282M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$34.94M	$40.17M	$13.26M
YoY Change	68.91%	128.63%	-27.22%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.249M	$2.300M	$2.460M
YoY Change	-7.64%	-10.16%	-6.0%
Goodwill	$189.0K
YoY Change	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$122.0K	$120.0K	$92.00K
YoY Change	34.07%	33.33%	-1.08%
Total Long-Term Assets	$3.051M	$3.240M	$3.633M
YoY Change	-18.44%	-20.0%	-16.1%
TOTAL ASSETS
Total Short-Term Assets	$34.94M	$40.17M	$13.26M
Total Long-Term Assets	$3.051M	$3.240M	$3.633M
Total Assets	$37.99M	$43.41M	$16.90M
YoY Change	55.53%	100.79%	-25.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.420M	$990.0K	$2.867M
YoY Change	1.94%	-27.21%	-20.76%
Accrued Expenses	$3.503M	$2.750M	$2.747M
YoY Change	11.92%	19.05%	-6.18%
Deferred Revenue	$1.103M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.139M	$1.556M	$389.0K
YoY Change	4178.0%	2122.86%	386.25%
Total Short-Term Liabilities	$9.165M	$6.590M	$7.021M
YoY Change	45.15%	19.6%	-10.55%
LONG-TERM LIABILITIES
Long-Term Debt	$4.830M	$5.368M	$6.635M
YoY Change	-28.87%
Other Long-Term Liabilities	$138.0K	$1.780M	$87.00K
YoY Change	28.97%	-77.44%	-57.56%
Total Long-Term Liabilities	$4.968M	$5.368M	$6.722M
YoY Change	4542.99%	-31.96%	3179.02%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.165M	$6.590M	$7.021M
Total Long-Term Liabilities	$4.968M	$5.368M	$6.722M
Total Liabilities	$16.60M	$13.74M	$18.28M
YoY Change	-7.25%	2.61%	15.7%
SHAREHOLDERS EQUITY
Retained Earnings	-$144.2M		-$123.3M
YoY Change	25.5%		29.77%
Common Stock	$60.00K		$22.00K
YoY Change	172.73%		-79.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$21.39M	$29.67M	-$1.383M
YoY Change
Total Liabilities & Shareholders Equity	$37.99M	$43.41M	$16.90M
YoY Change	55.53%	100.78%	-25.08%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2017 Q1
OPERATING ACTIVITIES
Net Income	-$8.978M	-$6.335M	-$8.302M
YoY Change	61.01%	-25.28%	127.39%
Depreciation, Depletion And Amortization	$430.0K	$420.0K	$475.0K
YoY Change	-10.42%	-10.64%	7.95%
Cash From Operating Activities	-$5.650M	-$8.720M	-$7.254M
YoY Change	27.25%	35.4%	6.83%
INVESTING ACTIVITIES
Capital Expenditures	-$110.0K	-$100.0K	$138.0K
YoY Change	-70.27%	-23.08%	-51.58%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$110.0K	-$100.0K	-$138.0K
YoY Change	-70.27%	-23.08%	-52.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	110.0K	31.54M	$2.000K
YoY Change	-98.75%	114.41%	-101.25%
NET CHANGE
Cash From Operating Activities	-5.650M	-8.720M	-$7.254M
Cash From Investing Activities	-110.0K	-100.0K	-$138.0K
Cash From Financing Activities	110.0K	31.54M	$2.000K
Net Change In Cash	-5.650M	22.72M	-$7.390M
YoY Change	-242.68%	179.12%	2.07%
FREE CASH FLOW
Cash From Operating Activities	-$5.650M	-$8.720M	-$7.254M
Capital Expenditures	-$110.0K	-$100.0K	$138.0K
Free Cash Flow	-$5.540M	-$8.620M	-$7.392M
YoY Change	36.12%	36.61%	4.48%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2017	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2017	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2017	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2017Q2	dei	Entity Public Float EntityPublicFloat	53439506	USD
CY2017	dei	Trading Symbol TradingSymbol	EKSO
CY2018Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	60216155	shares
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2249000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2435000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	91000	USD
CY2016Q4	us-gaap	Assets Assets	24425000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2374000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3130000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	825000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	20684000	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	60000	USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	22000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	165825000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-144154000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-114861000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	21391000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	6531000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	121291000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	37988000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	24425000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	34937000	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	502000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1339000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	1556000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	3025000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1780000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2760000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16846000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27813000	USD
CY2017Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	42000	USD
CY2016Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	217000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	79000	USD
CY2017Q4	ekso	Business Combination Contingent Success Fee Liability BusinessCombinationContingentSuccessFeeLiability	39000	USD
CY2016Q4	ekso	Business Combination Contingent Success Fee Liability BusinessCombinationContingentSuccessFeeLiability	116000	USD
CY2017Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	4830000	USD
CY2016Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	6789000	USD
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	1648000	USD
CY2016Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	3546000	USD
CY2017Q4	us-gaap	Notes Payable Current NotesPayableCurrent	2139000	USD
CY2016Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	7315000	USD
CY2017	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	38000	USD
CY2017	us-gaap	Cost Of Services CostOfServices	14000	USD
CY2017	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5284000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-29122000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-419000	USD
CY2015	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	4352000	USD
CY2016	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	13434000	USD
CY2015	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	4309000	USD
CY2015	us-gaap	Sales Revenue Net SalesRevenueNet	8661000	USD
CY2015	us-gaap	Cost Of Goods Sold CostOfGoodsSold	3926000	USD
CY2016	us-gaap	Cost Of Goods Sold CostOfGoodsSold	10715000	USD
CY2016	us-gaap	Cost Of Services CostOfServices	559000	USD
CY2017	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35609000	shares
CY2015	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14609000	shares
CY2016	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	11274000	USD
CY2016	us-gaap	Gross Profit GrossProfit	2947000	USD
CY2016	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	10997000	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8879000	USD
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10853000	USD
CY2016	us-gaap	Operating Expenses OperatingExpenses	30533000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-27586000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-19590000	USD
CY2015	us-gaap	Preferred Stock Amount Of Preferred Dividends In Arrears PreferredStockAmountOfPreferredDividendsInArrears	4655000	USD
CY2016	us-gaap	Preferred Stock Amount Of Preferred Dividends In Arrears PreferredStockAmountOfPreferredDividendsInArrears	10345000	USD
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24245000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	80000	USD
CY2017	us-gaap	Restructuring Costs RestructuringCosts	659000	USD
CY2015	us-gaap	Restructuring Costs RestructuringCosts	0	USD
CY2016	us-gaap	Restructuring Costs RestructuringCosts	0	USD
CY2017	ekso	Change In Fair Value Contingent Liabilities ChangeInFairValueContingentLiabilities	332000	USD
CY2015	ekso	Change In Fair Value Contingent Liabilities ChangeInFairValueContingentLiabilities	0	USD
CY2016	ekso	Change In Fair Value Contingent Liabilities ChangeInFairValueContingentLiabilities	196000	USD
CY2017	ekso	Gain Loss On Repurchase Of Warrants GainLossOnRepurchaseOfWarrants	-1067000	USD
CY2015	ekso	Gain Loss On Repurchase Of Warrants GainLossOnRepurchaseOfWarrants	0	USD
CY2016	ekso	Gain Loss On Repurchase Of Warrants GainLossOnRepurchaseOfWarrants	0	USD
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35609000	shares
CY2015	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14606000	shares
CY2016	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18126000	shares
CY2016	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18622000	shares
CY2016	us-gaap	Depreciation Depreciation	1855000	USD
CY2017	us-gaap	Depreciation Depreciation	1732000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	2414000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24997000	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	3121000	USD
CY2015	us-gaap	Depreciation Depreciation	933000	USD
CY2016	ekso	Transfer Of Property And Equipment To Inventory TransferOfPropertyAndEquipmentToInventory	11000	USD
CY2017	ekso	Amortization Of Deferred Rent AmortizationOfDeferredRent	-16000	USD
CY2016	ekso	Amortization Of Deferred Rent AmortizationOfDeferredRent	36000	USD
CY2017	us-gaap	Accretion Expense AccretionExpense	96000	USD
CY2016	us-gaap	Accretion Expense AccretionExpense	0	USD
CY2017	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	83000	USD
CY2016	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2017	ekso	Gain Loss On Change In Fair Value Contingent Liabilities GainLossOnChangeInFairValueContingentLiabilities	213000	USD
CY2016	ekso	Gain Loss On Change In Fair Value Contingent Liabilities GainLossOnChangeInFairValueContingentLiabilities	196000	USD
CY2017	ekso	Transfer Of Property And Equipment To Inventory TransferOfPropertyAndEquipmentToInventory	554000	USD
CY2017	ekso	Repurchase Of Warrants And Share Issuance RepurchaseOfWarrantsAndShareIssuance	2245000	USD
CY2016	ekso	Repurchase Of Warrants And Share Issuance RepurchaseOfWarrantsAndShareIssuance	0	USD
CY2017	ekso	Warrant Issued WarrantIssued	3301000	USD
CY2016	ekso	Warrant Issued WarrantIssued	0	USD
CY2017	ekso	Cumulative Retrospective Adjustment To Retained Earnings CumulativeRetrospectiveAdjustmentToRetainedEarnings	171000	USD
CY2016	ekso	Cumulative Retrospective Adjustment To Retained Earnings CumulativeRetrospectiveAdjustmentToRetainedEarnings	0	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-456000	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2706000	USD
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	10967000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19552000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-31226000	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1096000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	456000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1096000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	23307000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	42568000	USD
CY2017	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	81000	USD
CY2016	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	80000	USD
CY2017	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2016	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	173000	USD
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	46000	USD
CY2017	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	500000	USD
CY2016	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-135000	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	1731000	USD
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	577000	USD
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	200000	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	91000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1738000	USD
CY2015	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-493000	USD
CY2015	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1266000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1492000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25190000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18269000	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1492000	USD
CY2015	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	60000	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14124000	USD
CY2015	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-1000	USD
CY2015	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	225000	USD
CY2015	ekso	Amortization Of Deferred Rent AmortizationOfDeferredRent	37000	USD
CY2015	us-gaap	Accretion Expense AccretionExpense	0	USD
CY2015	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2015	ekso	Gain Loss On Change In Fair Value Contingent Liabilities GainLossOnChangeInFairValueContingentLiabilities	0	USD
CY2015	ekso	Transfer Of Property And Equipment To Inventory TransferOfPropertyAndEquipmentToInventory	0	USD
CY2015	ekso	Repurchase Of Warrants And Share Issuance RepurchaseOfWarrantsAndShareIssuance	0	USD
CY2015	ekso	Warrant Issued WarrantIssued	0	USD
CY2015	ekso	Cumulative Retrospective Adjustment To Retained Earnings CumulativeRetrospectiveAdjustmentToRetainedEarnings	0	USD
CY2017Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1562000	USD
CY2016Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1091000	USD
CY2017Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	0	USD
CY2016Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	198000	USD
CY2017Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1463000	USD
CY2016Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	267000	USD
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2850000	USD
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2303000	USD
CY2017Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	232000	USD
CY2016Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	203000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	130000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	52000	USD
CY2017Q4	ekso	Accrued Maintenance Current AccruedMaintenanceCurrent	121000	USD
CY2016Q4	ekso	Accrued Maintenance Current AccruedMaintenanceCurrent	483000	USD
CY2017Q4	ekso	Accrued Clinical Cost Current AccruedClinicalCostCurrent	136000	USD
CY2016Q4	ekso	Accrued Clinical Cost Current AccruedClinicalCostCurrent	35000	USD
CY2016Q4	ekso	Success Fee Expenses SuccessFeeExpenses	250000	USD
CY2016Q4	us-gaap	Share Price SharePrice	8.00
CY2017Q4	ekso	Contingent Success Fee Liability ContingentSuccessFeeLiability	39000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	5472000	USD
CY2017	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0905	pure
CY2017Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2139000	USD
CY2017Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	2333000	USD
CY2017Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	2333000	USD
CY2017Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	440000	USD
CY2017Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	7245000	USD
CY2017Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	276000	USD
CY2017Q4	us-gaap	Long Term Debt LongTermDebt	6969000	USD
CY2017Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2139000	USD
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4830000	USD
CY2017Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.00
CY2017Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	34000000	USD
CY2017Q3	ekso	Shares Subscription Description SharesSubscriptionDescription	1.1608
CY2017Q3	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	131000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	212000	USD
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	107000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	141429000	shares
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-33735000	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24246000	USD
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8302000	USD
CY2017Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5507000	USD
CY2017Q1	us-gaap	Sales Revenue Net SalesRevenueNet	1436000	USD
CY2017Q2	us-gaap	Sales Revenue Net SalesRevenueNet	1867000	USD
CY2017Q3	us-gaap	Sales Revenue Net SalesRevenueNet	1597000	USD
CY2017Q4	us-gaap	Sales Revenue Net SalesRevenueNet	2453000	USD
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6335000	USD
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	141429000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	59943000	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	59943000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21894000	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21894000	shares
CY2017	us-gaap	Interest Expense InterestExpense	648000	USD
CY2016	us-gaap	Interest Expense InterestExpense	16000	USD
CY2015	us-gaap	Interest Expense InterestExpense	13000	USD
CY2017	ekso	Warrant Issuance Expense WarrantIssuanceExpense	0	USD
CY2016	ekso	Warrant Issuance Expense WarrantIssuanceExpense	0	USD
CY2015	ekso	Warrant Issuance Expense WarrantIssuanceExpense	487000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29541000	USD
CY2016Q1	us-gaap	Sales Revenue Net SalesRevenueNet	8486000	USD
CY2016Q2	us-gaap	Sales Revenue Net SalesRevenueNet	1552000	USD
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	1596000	USD
CY2016Q4	us-gaap	Sales Revenue Net SalesRevenueNet	2587000	USD
CY2017Q1	us-gaap	Gross Profit GrossProfit	352000	USD
CY2017Q2	us-gaap	Gross Profit GrossProfit	396000	USD
CY2017Q3	us-gaap	Gross Profit GrossProfit	544000	USD
CY2017Q4	us-gaap	Gross Profit GrossProfit	777000	USD
CY2016Q1	us-gaap	Gross Profit GrossProfit	1498000	USD
CY2016Q2	us-gaap	Gross Profit GrossProfit	203000	USD
CY2016Q3	us-gaap	Gross Profit GrossProfit	403000	USD
CY2016Q4	us-gaap	Gross Profit GrossProfit	843000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-8302000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-5507000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-6335000	USD
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	-8978000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-3651000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-5765000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-8478000	USD
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	-5576000	USD
CY2017Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8978000	USD
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6775000	USD
CY2016Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9970000	USD
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11494000	USD
CY2016Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5576000	USD
CY2017Q4	us-gaap	Contractual Obligation ContractualObligation	10881000	USD
CY2017Q4	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	3224000	USD
CY2017Q4	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	6950000	USD
CY2017Q4	us-gaap	Contractual Obligation Due In Fifth Year ContractualObligationDueInFifthYear	707000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-26434000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-21458000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-19918000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-2688000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-2012000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	328000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-29122000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-23470000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-19590000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	40125000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2016Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0	pure
CY2017	ekso	Effective Income Tax Rate Reconciliation Unrealized Gain Loss On Warrant EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant	0.031	pure
CY2016	ekso	Effective Income Tax Rate Reconciliation Unrealized Gain Loss On Warrant EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant	0.062	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.004	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.004	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.005	pure
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	35973000	USD
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.012	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.009	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.005	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.189	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.408	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.384	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.591	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.023	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.003	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.001	pure
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2015	ekso	Effective Income Tax Rate Reconciliation Unrealized Gain Loss On Warrant EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant	0.043	pure
CY2017Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	242000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	61000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	31590000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	35647000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1359000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	872000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	524000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	951000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	253000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	246000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2277000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2430000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	42000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	86000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	314000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	168000	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	93000	USD
CY2014	ekso	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	4000	USD
CY2014	ekso	Unrecognized Tax Benefits Increases Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromCurrentPeriodTaxPositions	46000	USD
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	143000	USD
CY2015	ekso	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	-19000	USD
CY2015	ekso	Unrecognized Tax Benefits Increases Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromCurrentPeriodTaxPositions	75000	USD
CY2016	ekso	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	4000	USD
CY2016	ekso	Unrecognized Tax Benefits Increases Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromCurrentPeriodTaxPositions	132000	USD
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	199000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	335000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	22800000	USD
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	14218000	USD
CY2015	ekso	Stock Issued During Period Value Conversion Of Preferred Stock To Common Stock And Accretion Of Preferred Discount StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStockAndAccretionOfPreferredDiscount	1356000	USD
CY2015	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	779000	USD
CY2015	ekso	Convertible Preferred Stock Beneficial Conversion Feature ConvertiblePreferredStockBeneficialConversionFeature	4655000	USD
CY2016	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	10827000	USD
CY2016	ekso	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits	0	USD
CY2015	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	1071000	USD
CY2015	ekso	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	53000	USD
CY2016	ekso	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	3188000	USD
CY2017	ekso	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	174000	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	225000	USD
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	110000	USD
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	46000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	3121000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1731000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2414000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	8808000	USD
CY2017	ekso	Stock Issued During Period Value Equiposis Supply And Sales Earnouts StockIssuedDuringPeriodValueEquiposisSupplyAndSalesEarnouts	237000	USD
CY2017	ekso	Stock Issued During Period Value New Issuesnet Of Issuance Costs StockIssuedDuringPeriodValueNewIssuesnetOfIssuanceCosts	33773000	USD
CY2017	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	0	USD
CY2016	ekso	Stock Issued During Period Value Conversion Of Preferred Stock To Common Stock And Accretion Of Preferred Discount StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStockAndAccretionOfPreferredDiscount	10345000	USD
CY2016	ekso	Convertible Preferred Stock Beneficial Conversion Feature ConvertiblePreferredStockBeneficialConversionFeature	10345000	USD
CY2016	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	14694000	USD
CY2017	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11058000	USD
CY2016	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	1373000	USD
CY2017	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	662000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	227000	USD
CY2017	ekso	Increase Decrease Fair Value Of Warrants IncreaseDecreaseFairValueOfWarrants	1837000	USD
CY2017	ekso	Gain Loss On Warrant Liability GainLossOnWarrantLiability	3909000	USD
CY2016	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1825000	USD
CY2015	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	57000	USD
CY2017	ekso	Common Stock Contribution CommonStockContribution	509000	USD
CY2016	ekso	Common Stock Contribution CommonStockContribution	0	USD
CY2015	ekso	Common Stock Contribution CommonStockContribution	0	USD
CY2017	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	113000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6417000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5811000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4168000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3376000	USD
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1732000	USD
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1855000	USD
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	933000	USD
CY2017	us-gaap	Inventory Write Down InventoryWriteDown	73000	USD
CY2016	us-gaap	Inventory Write Down InventoryWriteDown	30000	USD
CY2015	us-gaap	Inventory Write Down InventoryWriteDown	34000	USD
CY2017Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	34000	USD
CY2016Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	54000	USD
CY2017	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	105000	USD
CY2016	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	14000	USD
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2414000	USD
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3121000	USD
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1731000	USD
CY2016Q4	ekso	Product Maintenance Warranty Liabilities Current Noncurrent ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent	687000	USD
CY2017	ekso	Product Maintenance Warranty Addition ProductMaintenanceWarrantyAddition	207000	USD
CY2017	ekso	Product Maintenance Warranty Expense ProductMaintenanceWarrantyExpense	408000	USD
CY2017Q4	ekso	Product Maintenance Warranty Liabilities Current Noncurrent ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent	353000	USD
CY2017Q4	ekso	Product Maintenance Warranty Liabilities Current ProductMaintenanceWarrantyLiabilitiesCurrent	353000	USD
CY2017Q4	ekso	Product Maintenance Warranty Liabilities Noncurrent ProductMaintenanceWarrantyLiabilitiesNoncurrent	0	USD
CY2017	ekso	Product Maintenance Adjustment From Remeasurement ProductMaintenanceAdjustmentFromRemeasurement	133000	USD
CY2015	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	1022000	USD
CY2015	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	53000	USD
CY2017	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2016	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	6930000	USD
CY2015	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-5638000	USD
CY2017	us-gaap	Income Taxes Paid IncomeTaxesPaid	429000	USD
CY2016	us-gaap	Income Taxes Paid IncomeTaxesPaid	16000	USD
CY2015	us-gaap	Income Taxes Paid IncomeTaxesPaid	12000	USD
CY2017	us-gaap	Interest Paid Net InterestPaidNet	20000	USD
CY2016	us-gaap	Interest Paid Net InterestPaidNet	33000	USD
CY2015	us-gaap	Interest Paid Net InterestPaidNet	5000	USD
CY2017	ekso	Supply Earnout SupplyEarnout	189000	USD
CY2016	ekso	Supply Earnout SupplyEarnout	0	USD
CY2015	ekso	Supply Earnout SupplyEarnout	0	USD
CY2015Q4	ekso	Product Maintenance Warranty Liabilities Current Noncurrent ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent	0	USD
CY2016	ekso	Product Maintenance Warranty Addition ProductMaintenanceWarrantyAddition	1341000	USD
CY2016	ekso	Product Maintenance Warranty Expense ProductMaintenanceWarrantyExpense	654000	USD
CY2016Q4	ekso	Product Maintenance Warranty Liabilities Current ProductMaintenanceWarrantyLiabilitiesCurrent	686000	USD
CY2016Q4	ekso	Product Maintenance Warranty Liabilities Noncurrent ProductMaintenanceWarrantyLiabilitiesNoncurrent	1000	USD
CY2017	ekso	Sales Earnout SalesEarnout	47000	USD
CY2016	ekso	Sales Earnout SalesEarnout	0	USD
CY2015	ekso	Sales Earnout SalesEarnout	0	USD
CY2017	ekso	Transferofwarrantliabilitytoequity Transferofwarrantliabilitytoequity	62000	USD
CY2016	ekso	Transferofwarrantliabilitytoequity Transferofwarrantliabilitytoequity	1363000	USD
CY2015	ekso	Transferofwarrantliabilitytoequity Transferofwarrantliabilitytoequity	0	USD
CY2017	ekso	Issuance Of Preferred Stock Warrants IssuanceOfPreferredStockWarrants	0	USD
CY2016	ekso	Issuance Of Preferred Stock Warrants IssuanceOfPreferredStockWarrants	0	USD
CY2015	ekso	Issuance Of Preferred Stock Warrants IssuanceOfPreferredStockWarrants	11700000	USD
CY2017	ekso	Beneficial Conversion Feature On Issuance Of Preferred Stock BeneficialConversionFeatureOnIssuanceOfPreferredStock	0	USD
CY2016	ekso	Beneficial Conversion Feature On Issuance Of Preferred Stock BeneficialConversionFeatureOnIssuanceOfPreferredStock	10345000	USD
CY2015	ekso	Beneficial Conversion Feature On Issuance Of Preferred Stock BeneficialConversionFeatureOnIssuanceOfPreferredStock	4655000	USD
CY2017	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2016	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	3000	USD
CY2015	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2017	ekso	Contingent Success Fee Liability For Term Loan ContingentSuccessFeeLiabilityForTermLoan	0	USD
CY2016	ekso	Contingent Success Fee Liability For Term Loan ContingentSuccessFeeLiabilityForTermLoan	116000	USD
CY2015	ekso	Contingent Success Fee Liability For Term Loan ContingentSuccessFeeLiabilityForTermLoan	0	USD
CY2017	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	0	USD
CY2016	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	0	USD
CY2015	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	1839000	USD
CY2017	ekso	Acquisitionofpropertyandequipmentwithcapitallease Acquisitionofpropertyandequipmentwithcapitallease	0	USD
CY2016	ekso	Acquisitionofpropertyandequipmentwithcapitallease Acquisitionofpropertyandequipmentwithcapitallease	0	USD
CY2015	ekso	Acquisitionofpropertyandequipmentwithcapitallease Acquisitionofpropertyandequipmentwithcapitallease	166000	USD
CY2016	us-gaap	Cost Of Property Repairs And Maintenance CostOfPropertyRepairsAndMaintenance	911000	USD
CY2015	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	0	USD
CY2016Q4	ekso	Accrueds Restructuring Current AccruedsRestructuringCurrent	0	USD
CY2017	us-gaap	Restructuring Charges RestructuringCharges	659000	USD
CY2017	us-gaap	Payments For Restructuring PaymentsForRestructuring	473000	USD
CY2016	ekso	Gain Loss On Warrant Liability GainLossOnWarrantLiability	4286000	USD
CY2015	ekso	Gain Loss On Warrant Liability GainLossOnWarrantLiability	2505000	USD
CY2017	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	-186000	USD
CY2017Q4	ekso	Accrueds Restructuring Current AccruedsRestructuringCurrent	0	USD
CY2017Q2	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated RestructuringAndRelatedCostNumberOfPositionsEliminated	27	pure
CY2017	us-gaap	Severance Costs1 SeveranceCosts1	473000	USD
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Use of Estimates</font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to: revenue recognition, deferred revenue and the deferral of associated costs, valuation of acquired intangible assets and goodwill, useful lives assigned to long-lived assets, realizability of deferred tax assets, valuation of common and preferred stock warrants, the valuation of options, and contingencies. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Concentration of Credit Risk and Other Risks and Uncertainties</font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains our cash accounts in excess of federally insured limits. However, the Company believes it is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held.  The Company extends credit to customers in the normal course of business and performs ongoing credit evaluations of its customers. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the consolidated financial statements. The Company does not require collateral from its customers to secure accounts receivable.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Accounts receivable are derived from the sale of products shipped and services performed for customers located in the U.S. and throughout the world. Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and provides an allowance for potential credit losses. The Company has not experienced material losses related to accounts receivable during the years ended December 31, 2017 and December 31, 2016. Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar. The Company does not enter into any foreign currency hedging agreements and is susceptible to gains and losses from foreign currency fluctuations. To date, the Company has not experienced significant gains or losses upon settling foreign contracts.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">   </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">At December 31, 2017, the Company had one customer with an accounts receivable balance totaling <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% or more of the Company’s total accounts receivable (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font>%) compared with three customers at December 31, 2016 (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">18</font>%, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 16</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 11</font>%) and one customer at December 31, 2015 (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font>%).</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company had no customers with sales of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font></font>% or more of the Company’s total revenue for the years ended December 31, 2017 and 2016, and one customer for the year ended December 31, 2015 (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">33</font>%).</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017	us-gaap	Advertising Expense AdvertisingExpense	160000	USD
CY2016	us-gaap	Advertising Expense AdvertisingExpense	108000	USD
CY2015	us-gaap	Advertising Expense AdvertisingExpense	25000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-419000	USD
CY2017Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	73000	USD
CY2016Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	60000	USD
CY2017Q4	us-gaap	Deferred Revenue DeferredRevenue	1919000	USD
CY2016Q4	us-gaap	Deferred Revenue DeferredRevenue	1630000	USD
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7168000	shares
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4440000	shares
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5802000	shares
CY2017	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	USD
CY2016	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	-4286000	USD
CY2015	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	-2505000	USD
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-29122000	USD
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-38101000	USD
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-26750000	USD
CY2017	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2016	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	496000	shares
CY2015	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	3000	shares
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.82
CY2016	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.87
CY2015	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.66
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.82
CY2016	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.05
CY2015	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.83
CY2016Q4	us-gaap	Business Combination Contingent Consideration Arrangements Range Of Outcomes Value Low BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow	157000	USD
CY2016Q4	us-gaap	Business Combination Contingent Consideration Arrangements Range Of Outcomes Value High BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh	521000	USD
CY2017	us-gaap	Business Combination Consideration Transferred Other1 BusinessCombinationConsiderationTransferredOther1	1071000	USD
CY2017Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	768000	USD
CY2017	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	1839000	USD
CY2017Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	40000	USD
CY2017Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	1610000	USD
CY2017Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets	1650000	USD
CY2017Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	1839000	USD
CY2015	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	1839000	USD
CY2016	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	112000	shares
CY2017Q3	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	509000	USD
CY2015	us-gaap	Fair Value Inputs Discount Rate FairValueInputsDiscountRate	0.15	pure
CY2017	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	500000	USD
CY2017Q4	us-gaap	Business Acquisition Share Price BusinessAcquisitionSharePrice	7.00
CY2017	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P3Y
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	535000	USD
CY2016	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	558000	USD
CY2015	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	26000	USD
CY2017	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	66000	USD
CY2016	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	146000	USD
CY2015	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	50000	USD
CY2017Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	31000	USD
CY2016Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	23000	USD
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Period Increase Decrease ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease	5400000	shares
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	486000	USD
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	400000	USD
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	342000	USD
CY2016Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	3597000	shares
CY2017	ekso	Class Of Warrant Or Right Issued ClassOfWarrantOrRightIssued	2066000	shares
CY2017	ekso	Class Of Warrant Or Right Repurchased ClassOfWarrantOrRightRepurchased	-1866000	shares
CY2017	us-gaap	Lessee Leasing Arrangements Operating Leases Term Of Contract LesseeLeasingArrangementsOperatingLeasesTermOfContract	P5Y
CY2017	ekso	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	371000	shares
CY2017Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	3396000	shares
CY2017	us-gaap	Lessee Leasing Arrangements Operating Leases Renewal Term LesseeLeasingArrangementsOperatingLeasesRenewalTerm	P5Y
CY2017	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-7 reverse
CY2017Q4	ekso	Stock Issued During Period Reverse Stock Splits Description StockIssuedDuringPeriodReverseStockSplitsDescription	On October 30, 2017, the Board approved an amendment to the Company’s Articles of Incorporation to increase the number of shares of our common stock by 70,000 shares to 141,429 shares (the “Authorized Capital Amendment”), subject to the approval of such amendment by the stockholders. On December 21, 2017, a special meeting of the stockholders was convened (the “December Special Meeting”). In the definitive proxy statement dated November 24, 2017 filed by us with the SEC in respect of the December Special Meeting (the “November Proxy Statement”), the Board solicited the vote of the stockholders in favor of the Authorized Capital Amendment. The November Proxy Statement stated that broker non-votes in respect of the Authorized Capital Amendment would be counted as votes against the amendment. However, under relevant stock exchange rules, brokers had the discretionary authority to vote any shares held in their name on behalf of a beneficial owner (“Broker Shares”), and in respect of which the broker did not receive voting instruction from the beneficial owner, in favor of the Authorized Capital Amendment. As such, brokers voted approximately 17,628 Broker Shares, in respect of which the brokers had not received voting instructions from the beneficial owners of such shares, in favor of the Authorized Capital Amendment at the December Special Meeting. Accordingly, after taking into account such Broker Shares, the Authorized Capital Amendment was approved by the stockholders at the December Special Meeting. However, as disclosed in more detail under Item 3 to this Annual Report on Form 10-K, some stockholders of the Company have claimed that the disclosure in the November Proxy Statement in connection with the effect on the Authorized Capital Amendment of beneficial owners not providing voting instructions in respect of their Broker Shares was incorrect. Accordingly, stockholders will be asked to vote again on the Authorized Capital Amendment our 2018 Annual Meeting of Shareholders. Further information about such vote will be provided in the Company’s Proxy Statement relating to its 2018 Annual Meeting of Shareholders, to be filed with the SEC within 120 days of December 31, 2017.
CY2015Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2122000	shares
CY2015Q4	ekso	Gross Proceeds From Preferred Stock And Warrants GrossProceedsFromPreferredStockAndWarrants	15000000	USD
CY2015Q4	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	13906000	USD
CY2015Q4	ekso	Stock Related Expenses Payable StockRelatedExpensesPayable	173000	USD
CY2015Q4	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	141	shares
CY2015Q4	ekso	Preferred Stock Converted Into Common Stock PreferredStockConvertedIntoCommonStock	3300000	shares
CY2016Q3	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	267	shares
CY2016	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	1389000	shares
CY2016	ekso	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	7.07
CY2015	ekso	Preferred Stock Converted Into Common Stock PreferredStockConvertedIntoCommonStock	2000	shares
CY2015	ekso	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	7.07
CY2015	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1355000	USD
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	15000	shares
CY2017	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	921000	shares
CY2017Q2	ekso	Payments For Repurchase Of Warrants Per Share PaymentsForRepurchaseOfWarrantsPerShare	1.23
CY2017Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	11700000	USD
CY2017	ekso	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	-30000	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	948000	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	1872000	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	211000	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	151000	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	4838000	shares
CY2016Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	3156000	shares
CY2016Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	1581000	shares
CY2017Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	4.96
CY2017Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	6.35
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0183	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0124	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0141	pure
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0237	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0237	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0250	pure
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.77	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.77	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.73	pure
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.88	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.83	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.76	pure
CY2017	us-gaap	Restricted Cash And Cash Equivalent Item Agreement RestrictedCashAndCashEquivalentItemAgreement	Of the 760 RSUs granted and 132 RSUs vested during the year ended December 31, 2017, 120 were granted and 115 vested to employees terminated in connection with the restructuring in May 2017.
CY2017Q3	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1	pure
CY2017Q3	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.5	pure
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	70000000	shares
CY2015	ekso	Adjustments To Additional Paid In Capital Issuance Of Warrants AdjustmentsToAdditionalPaidInCapitalIssuanceOfWarrants	11700000	USD
CY2017	ekso	Adjustments To Additional Paid In Capital Issuance Of Warrants AdjustmentsToAdditionalPaidInCapitalIssuanceOfWarrants	3301000	USD
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	42463000	USD
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14694000	USD
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2017	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	0	USD
CY2016	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	0	USD
CY2015	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	13906000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	3300000	USD
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	296000	USD
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-166000	USD
CY2015	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-45000	USD
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2490000	USD
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4116000	USD
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1971000	USD
CY2017	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	USD
CY2016	us-gaap	Investment Income Interest InvestmentIncomeInterest	12000	USD
CY2015	us-gaap	Investment Income Interest InvestmentIncomeInterest	11000	USD
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.38
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.22
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
CY2017Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2016Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.61
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.60
CY2016Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
CY2016Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.61
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.60
CY2016Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.35
CY2017	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4153	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	17220	USD
CY2017	ekso	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	33000	USD
CY2017	ekso	Unrecognized Tax Benefits Increases Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromCurrentPeriodTaxPositions	119000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	487000	USD
CY2016	ekso	Reduction In Net Loss Attributable To Common Stock Holders ReductionInNetLossAttributableToCommonStockHolders	2358000	USD
CY2016	ekso	Reductionin Net Loss Per Share Attributable Tocommon Stock Holders ReductioninNetLossPerShareAttributableTocommonStockHolders	0.13
CY2017	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P7Y8M5D

Files In Submission

Name	View Source	Status
0001144204-18-014386-index-headers.html	Edgar Link	pending
0001144204-18-014386-index.html	Edgar Link	pending
0001144204-18-014386.txt	Edgar Link	pending
0001144204-18-014386-xbrl.zip	Edgar Link	pending
ekso-20171231.xml	Edgar Link	completed
ekso-20171231.xsd	Edgar Link	pending
ekso-20171231_cal.xml	Edgar Link	unprocessable
ekso-20171231_def.xml	Edgar Link	unprocessable
ekso-20171231_lab.xml	Edgar Link	unprocessable
ekso-20171231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv487296_10k.htm	Edgar Link	pending
tv487296_ex21-1.htm	Edgar Link	pending
tv487296_ex23-1.htm	Edgar Link	pending
tv487296_ex31-1.htm	Edgar Link	pending
tv487296_ex31-2.htm	Edgar Link	pending
tv487296_ex32-1.htm	Edgar Link	pending
tv487296_ex32-2.htm	Edgar Link	pending
tv487296_img01.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EKSO
EKSO BIONICS HOLDINGS, INC. Stock $ekso

2017 Q4 Form 10-K Financial Statement

#000114420418014386 Filed on March 13, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EKSO EKSO BIONICS HOLDINGS, INC. Stock $ekso

2017 Q4 Form 10-K Financial Statement

#000114420418014386 Filed on March 13, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EKSO
EKSO BIONICS HOLDINGS, INC. Stock $ekso